“After the introduction of once-weekly semaglutide in Denmark in November 2018, the annual number of first-time NAION episodes reached an all-time high for the years 2019 through 2023.”
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Biomea Fusion announced a clinical hold by the U.S. FDA on its diabetes drug trial due to potential toxic liver disease, causing a 60% drop in its shares.
In a stark reflection of diabetes screening gaps, more than one-quarter of U.S. adults with diabetes remained undiagnosed in 2021-2023, with obesity linked to a nearly four-fold higher prevalence compared to normal-weight individuals.